Date | Title | Description | Source |
19.04.2024 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ... | einpresswi... |
22.03.2024 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ... | einpresswi... |
10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approva... | medcitynew... |
01.03.2024 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | einpresswi... |
28.02.2024 | Iovance Biotherapeutics Reports Fourth Quarter and Full Year... | Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) A... | einpresswi... |
21.02.2024 | A watershed moment for cancer therapies has arrived | A new class of cancer treatments that harness the body's immune system to fight tumors is being hail... | axios.com/... |
20.02.2024 | Iovance Biotherapeutics, Inc. Announces Pricing of $211 Mill... | - | globenewsw... |
20.02.2024 | WuXi Advanced Therapies Receives FDA Approval to Manufacture... | AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval f... | en.prnasia... |
16.02.2024 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (... | einpresswi... |
17.11.2023 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | einpresswi... |
10.08.2023 | The Melanoma Research Foundation to Host the 2023 Philadelph... | Philadelphia Miles for Melanoma
PHILADELPHIA (PRWEB) August 10, 2023
The Melanoma Research Foundatio... | prweb.com/... |
21.07.2023 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | /EIN News/ -- SAN CARLOS, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (N... | einpresswi... |
13.07.2023 | Iovance Biotherapeutics Announces Closing of $172.5 Million ... | - | globenewsw... |
13.07.2023 | Iovance Biotherapeutics Announces Closing of $172.5 Million ... | Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million S... | einpresswi... |
11.07.2023 | Iovance Biotherapeutics, Inc. Announces Pricing of Its Publi... | /EIN News/ -- SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (N... | einpresswi... |
10.07.2023 | Iovance Biotherapeutics, Inc. Announces Pricing of Its Publi... | - | globenewsw... |
10.07.2023 | Iovance Biotherapeutics, Inc. Announces Proposed Public Offe... | /EIN News/ -- SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (N... | einpresswi... |
09.06.2023 | Iovance Biotherapeutics to Present at Jefferies Global Healt... | /EIN News/ -- SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (N... | einpresswi... |
09.05.2023 | Iovance Biotherapeutics Reports First Quarter 2023 Financial... | /EIN News/ -- First Biologics License Application (BLA) Submission Completed in March 2023
Commercia... | einpresswi... |
02.05.2023 | Iovance Biotherapeutics to Host First Quarter 2023 Financial... | /EIN News/ -- SAN CARLOS, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NA... | einpresswi... |
24.03.2023 | Iovance Biotherapeutics Completes Biologics License Applicat... | SAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. IOVA, a late-st... | einpresswi... |
28.02.2023 | Iovance Biotherapeutics Reports Fourth Quarter and Full Year... | First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
/EIN News/ -- SAN ... | einpresswi... |
18.11.2022 | Iovance Biotherapeutics Provides Update on Biologics License... | BLA Submission Ongoing with U.S. Food and Drug Administration
/EIN News/ -- SAN CARLOS, Calif., Nov.... | einpresswi... |
24.10.2022 | Iovance Biotherapeutics to Host Third Quarter Financial Resu... | SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
10.10.2022 | Iovance Biotherapeutics Announces First Patient Dosed with P... | First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression
SAN ... | globenewsw... |
05.10.2022 | Iovance Biotherapeutics to Present Clinical Data for Lifileu... | Oral Presentation of C-144-01 Trial Cohorts 2 and 4
/EIN News/ -- SAN CARLOS, Calif., Oct. 05, 2022 ... | einpresswi... |
05.10.2022 | Iovance Biotherapeutics to Present Clinical Data for Lifileu... | SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
06.09.2022 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
06.09.2022 | Iovance Biotherapeutics to Present Posters at ESMO 2022 | SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
25.08.2022 | Iovance Biotherapeutics Initiates Biologics License Applicat... | First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration
Complete BLA Submi... | globenewsw... |
04.08.2022 | Iovance Biotherapeutics Reports Second Quarter and First Hal... | First Biologics License Application (BLA) Submission on Track in August 2022
SAN CARLOS, Calif., Aug... | globenewsw... |
27.07.2022 | Iovance Biotherapeutics to Host Second Quarter Financial Res... | SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
22.07.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
17.06.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
13.06.2022 | Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to B... | SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
08.06.2022 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
27.05.2022 | Iovance Stock Tumbles on Cancer Data. Analysts Say the Sello... | Iovance Biotherapeutics stock lost nearly half its value after the company announced results from a ... | barrons.co... |
26.05.2022 | Iovance Biotherapeutics Announces Positive Clinical Data for... | Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in
Coh... | globenewsw... |
20.05.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a... | globenewsw... |
05.05.2022 | Iovance Biotherapeutics Reports First Quarter 2022 Financial... | SAN CARLOS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a... | globenewsw... |
27.04.2022 | Iovance Biotherapeutics to Present Translational Data for Li... | SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
26.04.2022 | Iovance Biotherapeutics to Host First Quarter Financial Resu... | SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
25.04.2022 | Iovance Biotherapeutics to Present at Chardan Genetic Medici... | SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
22.04.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
05.04.2022 | Iovance Biotherapeutics Announces Regulatory and Clinical Up... | Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission
Further Defines Frontline Me... | globenewsw... |
16.03.2022 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
15.03.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
15.03.2022 | Iovance Biotherapeutics’ Investigational New Drug Applicatio... | Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliv... | globenewsw... |
24.02.2022 | Iovance Biotherapeutics Reports Fourth Quarter and Full Year... | SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
18.02.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
11.02.2022 | Iovance Biotherapeutics to Host Fourth Quarter and Full Year... | SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
21.01.2022 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
10.01.2022 | Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. t... | SAN CARLOS, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
07.01.2022 | Iovance Biotherapeutics to Present Data on Tumor-Infiltratin... | TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped ... | globenewsw... |
06.01.2022 | Iovance Biotherapeutics to Present at the 40th Annual J.P. M... | SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
17.12.2021 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
07.12.2021 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
19.11.2021 | Iovance Biotherapeutics Reports Inducement Grants under NASD... | SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
14.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Lifileuc... | Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpo... | marketscre... |
13.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Lifileuc... | Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpo... | globenewsw... |
12.11.2021 | Iovance Biotherapeutics Announces Clinical Data for LN-145 i... | 21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastati... | marketscre... |
12.11.2021 | Iovance Biotherapeutics Announces Clinical Data for LN-145 i... | 21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastati... | globenewsw... |
09.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Tumor In... | TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naï... | globenewsw... |
09.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Tumor In... | TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naï... | marketscre... |
08.11.2021 | Iovance Biotherapeutics to Present at Upcoming Conferences | SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
04.11.2021 | Iovance Biotherapeutics Reports Third Quarter and Year-to-Da... | SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
04.11.2021 | Iovance Biotherapeutics Reports Third Quarter and Year-to-Da... | Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021
Financial Results and Corporate ... | marketscre... |
04.11.2021 | 2020 Annual Report | TIL CELL THERAPY
DEDICATED TO THE FIGHT
AGAINST SOLID TUMORS
2020 ANNUAL REPORT
IOVANCE'S
DEDICATION... | marketscre... |
04.11.2021 | Iovance Biotherapeutics Reports Third Quarter and Year-to-Da... | SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | marketscre... |
25.10.2021 | Iovance Biotherapeutics to Host Third Quarter Financial Resu... | SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
18.10.2021 | Iovance Biotherapeutics to Host Conference Call and Webcast ... | Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab
in Immune-Checkpoint In... | globenewsw... |
29.09.2021 | Iovance Biotherapeutics : Celebrates Grand Opening of Iovanc... | Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders
Largest... | marketscre... |
06.08.2021 | Iovance Biotherapeutics : Reports Second Quarter and First H... | Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T ... | marketscre... |
05.08.2021 | Iovance Biotherapeutics : Reports Second Quarter and First H... | SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | marketscre... |
29.06.2021 | Iovance Biotherapeutics Announces Clinical Data for LN-145 i... | 21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSC... | marketscre... |
07.06.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics : Ann... | SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology compan... | marketscre... |
06.06.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Annou... | Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 i... | marketscre... |
04.06.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Annou... | 86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) ... | marketscre... |
20.05.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Annou... | 86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoin... | marketscre... |
20.05.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics : Ann... | SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology compan... | marketscre... |
07.05.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics : Rep... | Iovance Biotherapeutics Reports First Quarter 2021
Financial Results and Corporate Updates
Expanding... | marketscre... |
06.05.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Repor... | SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a... | marketscre... |
09.04.2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Annou... | Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-14... | marketscre... |
01.03.2021 | Iovance Biotherapeutics to Present at Upcoming Healthcare Co... | SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),... | globenewsw... |
18.02.2021 | Iovance Biotherapeutics to Host Fourth Quarter and Full Year... | SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ... | globenewsw... |
13.08.2020 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics : Aug... | Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer
August 2020
Forwar... | marketscre... |
02.07.2019 | Emboldened by ASCO data, FDA etches speedy approval pa... | Iovance’s promising data snapshot detailing the potential of its cervical cancer drug at ... | endpts.com... |
30.05.2019 | After generating ASCO fervor, Iovance unveils plans ... | After causing a stir weeks ago with its ASCO abstract that hinted at the potential supremac... | endpts.com... |
- | Stocks making the biggest moves midday: Nvidia, Tesla, Coinb... | Check out the companies making headlines in midday trading.
Nvidia — Shares of the chipmaker and art... | cnbc.com/2... |
- | Unleashing the immune system: Cell therapies for the diverse... | Evolution of cell therapies in cancer
Cellular therapies such as CAR-T cell therapy have transformed... | statnews.c... |